These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. ORBITA Trial: Redefining the Role of Intervention in the Treatment of Stable Coronary Disease? Albuquerque LC; Gomes WJ Braz J Cardiovasc Surg; 2018; 33(1):III-V. PubMed ID: 29617511 [No Abstract] [Full Text] [Related]
26. Is Exercise Treadmill Time or Reduction in Myocardial Ischemia the Appropriate Primary Endpoint to Assess Success of Percutaneous Coronary Intervention in Stable Angina (ORBITA)? Dilsizian V; Erario M J Nucl Med; 2018 Jan; 59(1):1-2. PubMed ID: 29217737 [No Abstract] [Full Text] [Related]
27. [Chronic coronary syndromes after the ISCHEMIA trial: what's new? The interventional cardiologist's point of view]. Indolfi C; Spaccarotella C G Ital Cardiol (Rome); 2020 Jun; 21(6):431-433. PubMed ID: 32425188 [No Abstract] [Full Text] [Related]
28. Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Bhatt DL; Gersh BJ; Steg PG; Harrington RA; Windecker S Circulation; 2018 Jun; 137(23):2427-2429. PubMed ID: 29669787 [No Abstract] [Full Text] [Related]
29. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Pursnani S; Korley F; Gopaul R; Kanade P; Chandra N; Shaw RE; Bangalore S Circ Cardiovasc Interv; 2012 Aug; 5(4):476-90. PubMed ID: 22872053 [TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Thomas S; Gokhale R; Boden WE; Devereaux PJ Can J Cardiol; 2013 Apr; 29(4):472-82. PubMed ID: 23010084 [TBL] [Abstract][Full Text] [Related]
31. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329 [TBL] [Abstract][Full Text] [Related]
32. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW; Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770 [TBL] [Abstract][Full Text] [Related]
33. Letter by Fan and He regarding article, "Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary disease and abnormal fractional flow reserve". Fan GX; Ge JB; He SS Circulation; 2014 Jun; 129(25):e683. PubMed ID: 24958759 [No Abstract] [Full Text] [Related]
34. Response to letter regarding article, "Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve". Fearon WF; Shilane D; Pijls NH; Boothroyd DB; Tonino PA; Barbato E; Juni P; De Bruyne B; Hlatky MA; Circulation; 2014 Jun; 129(25):e684. PubMed ID: 24958760 [No Abstract] [Full Text] [Related]
35. Long-term results following percutaneous myocardial laser therapy. Salem M; Rotevatn S; Nordrehaug JE Coron Artery Dis; 2006 May; 17(4):385-90. PubMed ID: 16707963 [TBL] [Abstract][Full Text] [Related]
36. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Di Sciascio G; Patti G; Pasceri V; Colonna G; Mangiacapra F; Montinaro A; Eur Heart J; 2010 Jun; 31(11):1337-43. PubMed ID: 20363764 [TBL] [Abstract][Full Text] [Related]
37. Last nail in the coffin for PCI in stable angina? Brown DL; Redberg RF Lancet; 2018 Jan; 391(10115):3-4. PubMed ID: 29103657 [No Abstract] [Full Text] [Related]
38. Letter: ORBITA-2 trial design and rationale: what causes angina after PCI? Milasinovic D; Stankovic G; Escaned J EuroIntervention; 2022 May; 18(1):94-95. PubMed ID: 35570689 [No Abstract] [Full Text] [Related]
39. Reply: ORBITA-2 trial design and rationale: what causes angina after PCI? Al-Lamee R EuroIntervention; 2022 May; 18(1):96. PubMed ID: 35570690 [No Abstract] [Full Text] [Related]